OLMA OLEMA PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - Clinical Study Results Olema Pharmaceuticals announced interim results from a clinical study of OP-1250 for the treatment of metastatic breast cancer, showing safety, tolerability, and efficacy.Get access to all SEC 8-K filings of the OLEMA PHARMACEUTICALS INC